New therapeutic strategy for chemotherapy resistance in ovarian cancer

byThe Wistar InstituteDr. Rugang Zhang. Credit: The Wistar InstituteA study from The Wistar Institute demonstrated that NAMPT, an enzyme critical for NAD+ biosynthesis, mediates selection of ste

Updated on: December 22,2023

New therapeutic strategy for chemotherapy resistance in ovarian cancer

byThe Wistar InstituteDr. Rugang Zhang. Credit: The Wistar InstituteA study from The Wistar Institute demonstrated that NAMPT, an enzyme critical for NAD+ biosynthesis, mediates selection of ste

Updated on:December 22,2023

Cancer test shows promise for bringing the benefits of immunotherapy to more patients

byBrigham and Women’s HospitalCredit: Pixabay/CC0 Public DomainImmunotherapy is a highly effective treatment for patients whose cancers harbor mismatch repair deficiency, and a new study identif

Updated on: January 25,2024

Cancer test shows promise for bringing the benefits of immunotherapy to more patients

byBrigham and Women’s HospitalCredit: Pixabay/CC0 Public DomainImmunotherapy is a highly effective treatment for patients whose cancers harbor mismatch repair deficiency, and a new study identif

Updated on:January 25,2024

Guideline updated for initial management of advanced prostate cancer

by Elana GotkineFor patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen depri

Updated on: January 08,2024

Guideline updated for initial management of advanced prostate cancer

by Elana GotkineFor patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen depri

Updated on:January 08,2024

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on: April 28,2024

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on:April 28,2024

Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stages

byVIB (the Flanders Institute for Biotechnology)The MM microenvironment is characterized by the presence of T cells with an exhausted phenotype. Credit:Journal of Hematology & Oncology

Updated on: December 02,2024

Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stages

byVIB (the Flanders Institute for Biotechnology)The MM microenvironment is characterized by the presence of T cells with an exhausted phenotype. Credit:Journal of Hematology & Oncology

Updated on:December 02,2024

Gene signature points to prognosis in kidney cancer

byKarolinska InstitutetSingle-cell landscape of the ecosystem in primary ccRCC and adjacent normal tissue.aExperimental design created with Biorender.com and Adobe Illustrator.

Updated on: December 25,2023

Gene signature points to prognosis in kidney cancer

byKarolinska InstitutetSingle-cell landscape of the ecosystem in primary ccRCC and adjacent normal tissue.aExperimental design created with Biorender.com and Adobe Illustrator.

Updated on:December 25,2023

Predicting DCIS upgrade to invasive cancer at breast surgery with ultrafast imaging

by American Roentgen Ray SocietyA) Preoperative breast MRI, initial DCE post-contrast axial fat-saturated T1 axial subtraction image, demonstrates 6 cm clumped enhancement surrounding biopsy clip

Updated on: January 28,2024

Predicting DCIS upgrade to invasive cancer at breast surgery with ultrafast imaging

by American Roentgen Ray SocietyA) Preoperative breast MRI, initial DCE post-contrast axial fat-saturated T1 axial subtraction image, demonstrates 6 cm clumped enhancement surrounding biopsy clip

Updated on:January 28,2024

Long-term study reveals more genetic mutations associated with aggressive prostate cancer

byInstitute of Cancer ResearchXenograft model of prostate cancer. Credit: National Institutes of Health, 2015Scientists have added to the list of inherited genetic mutations known to increase th

Updated on: July 08,2024

Long-term study reveals more genetic mutations associated with aggressive prostate cancer

byInstitute of Cancer ResearchXenograft model of prostate cancer. Credit: National Institutes of Health, 2015Scientists have added to the list of inherited genetic mutations known to increase th

Updated on:July 08,2024

Revealing one of the mechanisms by which thyroid cancer becomes resistant to lenvatinib-a

by Shinshu UniversityThe EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by len

Updated on: December 26,2023

Revealing one of the mechanisms by which thyroid cancer becomes resistant to lenvatinib-a

by Shinshu UniversityThe EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by len

Updated on:December 26,2023

Barriers to early clinical trial access for adolescents and young adults still exist

byEuropean Society for Medical OncologyYoung cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congre

Updated on: December 18,2023

Barriers to early clinical trial access for adolescents and young adults still exist

byEuropean Society for Medical OncologyYoung cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congre

Updated on:December 18,2023

3D genome features point to possible therapeutic target for aggressive and deadly pediatric brain tumors

by Fabienne Landry,McGill University Health CentreCredit:Cell(2024). DOI: 10.1016/j.cell.2024.06.023Posterior fossa group A (PFA) ependymoma are rare, treatment-resistant pediatric t

Updated on: July 11,2024

3D genome features point to possible therapeutic target for aggressive and deadly pediatric brain tumors

by Fabienne Landry,McGill University Health CentreCredit:Cell(2024). DOI: 10.1016/j.cell.2024.06.023Posterior fossa group A (PFA) ependymoma are rare, treatment-resistant pediatric t

Updated on:July 11,2024

Boosting immunotherapy in non-responsive cancer cells

by Surabhi Chandra,Indian Institute of ScienceAvik Chattopadhyay working in the lab. Credit: Nikita RamtekeCancer immunotherapy primes a patient's immune system to better find and destroy ca

Updated on: January 26,2024

Boosting immunotherapy in non-responsive cancer cells

by Surabhi Chandra,Indian Institute of ScienceAvik Chattopadhyay working in the lab. Credit: Nikita RamtekeCancer immunotherapy primes a patient's immune system to better find and destroy ca

Updated on:January 26,2024